It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery accelerates hit identification with Affinity Selection Mass Spectrometry, a pillar of our HIT SYNERGY Platform designed to unlock challenging targets and deliver confident starting points fast.
ASMS gives early discovery what it needs most: speed, confidence, and freedom from assay constraints.
We design and curate our own bespoke affinity screening libraries to provide rapid, cost-effective access to high – quality chemical diversity, including ideal starting points for new ligase and PROTAC ligands.
Why ASMS?
Fast
Our scalable, automatable workflows screen hundreds of compounds per well, dramatically accelerating timelines while keeping resource use low. Full campaigns, including confirmation using orthogonal biophysical assays, can be completed in 6 -8 weeks using minimal protein and reagents. It is speed without compromise.
Accurate
ASMS identifies binders by molecular formula using exact mass data, delivering confident hit identification with fewer artefacts than traditional activity-based methods. This label-free approach reduces false positives and removes guesswork giving you clarity from the start.
Target-Agnostic
ASMS thrives where other platforms stall. It supports virtually any drug target, including those not amenable to biochemical HTS, and excels with complex or non-protein systems such as nucleic acids. Running fully in solution and maintaining native target conformations, ASMS captures real binding events across orthosteric, allosteric, and cryptic sites.
Where ASMS Delivers Exceptional Value
Induced Proximity and Degrader Discovery ASMS is a powerful route t novel POI ligands and ligase warheads, making it an ideal entry point for degrader discovery. Hits can be seamlessly advanced into our CHARMED degrader platform for rapid triage and optimization.
A Smart Alternative to HTS When Biochemistry Falls Short
For enzymatically inert proteins, non-protein targets, or systems that resist traditional assay formats, ASMS offers a straightforward path to chemistry. It quickly reveals binders that seed medicinal chemistry or provide tool compounds for downstream assay development.
A Powerful Complement, or Alternative, to DEL
ASMS screens lead-like molecules directly, with hits immediately available for confirmation since no resynthesis is required. With unlabeled compounds and assays run fully in solution, ASMS avoids immobilization artifacts and remains compatible with DNA/RNA complexes, making it particularly effective for large, complex targets where DEL or traditional HTS may struggle.
Sygnature Screening Libraries
We currently have 215,000 molecules in pooled libraries, to provide excellent chemical space coverage and provide the best hits for any project. These compounds are formed from two screening libraries:
Our The LeadFinder Diversity Deck: includes 150,000 chemically diverse, lead like compounds. These low molecular weight compounds provide excellent chemical space coverage and provide attractive start points for chemical development., and the proprietary
The LeadFinder PRISM Deck: A proprietary deck of 65,000 high-Fsp3, scaffold-rich molecules, which are chemically tractable and likely to provide good selectivity profiles.
Using a pooling format s of 300 compounds per well, we unlock exceptional throughput without sacrificing chemical
In this poster, we demonstrate ASMS screening for novel VHL ligands as starting points for TPD programs. Download for more insights into how ASMS advances drug discovery by efficiently identifying high-affinity ligands.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.
Our Computer Aided Drug Design (CADD) capabilities combine deep scientific expertise with advanced AI, machine learning, and informatics infrastructure to support smarter, faster decision-making across the drug discovery pipeline.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
